CuraGen (CRGN) Message Board

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : CuraGen (CRGN)

Public Reply Prvt Reply Mark as Last Read File

Previous 10 PreviousNext

To: scaram(o)uche who wrote (477)	6/2/2009 4:20:32 PM
From: mlkr	of 478

yep! 1. Celldex acquires CuraGen for $94.5M By Maureen Martino Comment \| Forward Massachusetts-based Celldex Therapeutics is paying $94.5 million to acquire CuraGen. Celldex gains CuraGen's portfolio of 11 oncology-focused antibodies. Its most advanced therapy is CR011, which is currently in Phase II studies for breast cancer and unresectable stage III and IV melanoma. Curagen also brings a cash balance of at least $54.5 million to the table, which Celldex says will allow the company to advance its clinical development programs into 2012. "Celldex's expertise in developing novel antibody-based therapeutics will enable us to seamlessly integrate CuraGen's antibody programs into our Precision Targeted Immunotherapy Platform and selectively identify and advance the candidates we believe hold the most therapeutic promise," said Thomas Davis, M.D., Chief Medical Officer of Celldex. CuraGen CEO Dr. Timothy Shannon will join the Celldex board. Related Articles:

Report TOU Violation

Share This Post

Public Reply Prvt Reply Mark as Last Read File

Previous 10 PreviousNext